menu

Medical Industry Feature: Unleash the Truth About COPD

Be part of the knowledge.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free

Unleash the Truth About COPD

4 chapters
Play All
Chapter 1
Unleash the Truth About COPD
RestartResume

Even one moderate or severe COPD exacerbation can lead to a significant decline in lung function,1 damage beyond the lungs,2 and effects on a patient’s quality of life.3,4

Chapter 2
video Learn about the clinical impact as Dr. Han explores the data on how exacerbations can impact patients with COPD. for Segment 11655
Learn about the clinical impact as Dr. Han explores the data on how exacerbations can impact patients with COPD.
Chapter 3
video The effect of exacerbations can go beyond the lungs.  Learn about how else patients with COPD are impacted. for Segment 11655
The effect of exacerbations can go beyond the lungs. Learn about how else patients with COPD are impacted.
Chapter 4
video The patient-provider dialogue helps ensure appropriate care, but are we always on the same page?  Watch to learn more. for Segment 11655
The patient-provider dialogue helps ensure appropriate care, but are we always on the same page? Watch to learn more.
  • Sponsored by

  • Overview

    For patients with COPD, exacerbations can have an irreversible and sustained impact on their daily life.3,4 Additionally, exacerbations are often underreported.5 That’s why Dr. MeiLan Han is here to walk us through the importance of exacerbation recognition and prevention, the health and life burdens of exacerbations, and patient-physician communication gaps.

    References:

    1. Halpin DMG, Decramer M, Celli BR, et al. Effect of a single exacerbation on decline in lung function in COPD. Respir Med. 2017;128:85-91.
    2. Donaldson GC, Hurst JR, Smith CJ, Hubbard RB, Wedzicha JA. Increased risk of myocardial infarction and stroke following exacerbation of COPD. Chest. 2010;137(5):1091-1097.
    3. O’Donnell DE, Bertley JC, Chau LK, Webb KA. Qualitative aspects of exertional breathlessness in chronic airflow limitation: pathophysiologic mechanisms. Am J Respir Crit Care Med. 1997;155(1):109-115.
    4. Roche N. Activity limitation: a major consequence of dyspnoea in COPD. Eur Respir Rev. 2009;18(112):54-57.
    5. Leidy NK, Murray LT, Jones P, Sethi S. Performance of the EXAcerbations of chronic pulmonary disease tool patient-reported outcome measure in three clinical trials of chronic obstructive pulmonary disease. Ann Am Thorac Soc. 2014;11(3):316-325.

    ©2020 AstraZeneca. All rights reserved. US-42455 Last Updated 8/20

LIVE ON REACHMD RADIOBack to live radio

Loading...

Programs 10/25/20